Neonatal cholestasis in congenital pituitary hormone deficiency and isolated hypocortisolism: characterization of liver dysfunction and follow-up

Arq Bras Endocrinol Metabol. 2011 Nov;55(8):622-7. doi: 10.1590/s0004-27302011000800017.

Abstract

Introduction: Neonatal cholestasis due to endocrine diseases is infrequent and poorly recognized. Referral to the pediatric endocrinologist is delayed.

Objective: We characterized cholestasis in infants with congenital pituitary hormone deficiencies (CPHD), and its resolution after hormone replacement therapy (HRT).

Subjects and methods: Sixteen patients (12 males) were included; eleven with CPHD, and five with isolated central hypocortisolism.

Results: Onset of cholestasis occurred at a median age of 18 days of life (range 2-120). Ten and nine patients had elevated transaminases and γGT, respectively. Referral to the endocrinologist occurred at 32 days (range 1 - 72). Remission of cholestasis occurred at a median age of 65 days, whereas liver enzymes occurred at 90 days. In our cohort isolated, hypocortisolism was a transient disorder.

Conclusion: Cholestasis due to hormonal deficiencies completely resolved upon introduction of HRT. Isolated hypocortisolism may be a transient cause of cholestasis that needs to be re-evaluated after remission of cholestasis.

MeSH terms

  • Adrenal Insufficiency / etiology*
  • Adrenal Insufficiency / physiopathology
  • Age of Onset
  • Cholestasis / etiology*
  • Cholestasis / physiopathology
  • Female
  • Follow-Up Studies
  • Hormone Replacement Therapy / methods
  • Humans
  • Hydrocortisone / deficiency
  • Hydrocortisone / therapeutic use*
  • Hypopituitarism / congenital*
  • Hypopituitarism / drug therapy
  • Infant
  • Liver Diseases / etiology*
  • Liver Diseases / physiopathology
  • Male
  • Pituitary Hormones, Anterior / deficiency
  • Remission Induction
  • Retrospective Studies
  • Thyroxine / therapeutic use*
  • Treatment Outcome

Substances

  • Pituitary Hormones, Anterior
  • Thyroxine
  • Hydrocortisone